Trial Profile
A Phase II Study of SGN-15 (cBR96 – Doxorubicin Immunoconjugate) Combined With Gemzar Versus Single-Agent Gemzar in Patients With Advanced Ovarian Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Sep 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; SGN-15 (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Seagen
- 21 Oct 2011 Seattle Genetics as company and lead trial centre added as reported by ClinicalTrials.gov.
- 16 Sep 2005 New trial record.